This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Omnicell (OMCL) Gains From New Offerings Amid Cost Woes
by Zacks Equity Research
With the EnlivenHealth platform, Omnicell (OMCL) is gaining momentum with cross-selling and up-selling communication solutions to existing customers.
QIAGEN (QGEN) Advances Precision Medicine With New QIAseq Kit
by Zacks Equity Research
QIAGEN (QGEN) launches the new QIAseq Multimodal DNA/RNA Lib Kit, facilitating multiomic studies and advancing precision medicine.
3 Reasons Growth Investors Will Love ResMed (RMD)
by Zacks Equity Research
ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Teleflex's (TFX) Urolift Drives Market Share, Macro Woes Stay
by Zacks Equity Research
The commercialization of Teleflex's (TFX) UroLift in Japan has been a significant step toward making this therapy more broadly available to men suffering from BPH.
BioLife (BLFS) Progresses in Cell & Gene Therapy With CryoCase
by Zacks Equity Research
BioLife's (BLFS) latest product, CryoCase, is compatible with various downstream processing systems, including its own Signata CT-5.
Charles River (CRL) Launches Viral Vector Tech Transfer Program
by Zacks Equity Research
Charles River's (CRL) new Fast Track and Modular frameworks facilitate product development continuity via accelerated process transfer to its viral vector Center of Excellence.
Veeva Systems (VEEV) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performance by both segments.
Here's Why ResMed (RMD) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
QIAGEN (QGEN) Develops Test for Research and CDx Application
by Zacks Equity Research
QIAGEN's (QGEN) next-generation sequencing test aims to aid personalized medicine research in solid tumor types, including ovarian cancer, and improve decentralized testing capabilities.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED) led by strong musculoskeletal prospects and raised guidance.
Zimmer Biomet (ZBH) Unlocks Growth Plan for Future Success
by Zacks Equity Research
Zimmer Biomet (ZBH) outlines a path for compelling and long-term topline growth, improved operational profitability, and increased free cash flow generation.
Reasons to Hold Charles River (CRL) in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Charles River (CRL), owing to its acquisitions, thriving DSA segment and financial stability.
Inspira Technologies' (IINN) ART100 Gets FDA 510(k) Grant
by Zacks Equity Research
Inspira Technologies' (IINN) ART100 recent approval highlights the company's innovative advancements in medical technology.
Exact Sciences (EXAS) Witnesses Rising Expenses, Competition
by Zacks Equity Research
Exact Sciences (EXAS) has numerous competitors, given the large market for colorectal cancer screening.
Are Medical Stocks Lagging Mind Medicine MindMed (MNMD) This Year?
by Zacks Equity Research
Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.
Exact Sciences (EXAS) to Showcase Favorable Research Outcome
by Zacks Equity Research
Exact Sciences' (EXAS) latest study research result shows commitment to innovation and strategies that expand access to effective cancer screening and diagnostic tools for patients.
Here's Why Investors Should Retain ICON (ICLR) Stock Now
by Zacks Equity Research
Investors remain optimistic about ICON (ICLR) due to its impressive strategic pacts and stable solvency.
Zacks.com featured highlights include Carlisle Companies, ResMed, Booz Allen Hamilton and CrediCorp
by Zacks Equity Research
Carlisle Companies, ResMed, Booz Allen Hamilton and CrediCorp are part of the Zacks Screen of the Week article.
ResMed (RMD) Up 16.3% Since Last Earnings: Will it Continue?
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) led by strong growth in the U.S. mask and accessories business and its cloud-connected platforms.
Stereotaxis (STXS) Gets CE Recertification for Approved Products
by Zacks Equity Research
Stereotaxis' (STXS) receives updated EU Quality Management System Certificate, which demonstrates compliance with MDR.
Here's Why You Should Buy Boston Scientific (BSX) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Boston Scientific (BSX) due to its geographical expansions and impressive acquisitions.
Charles River (CRL) Banks on RMS Growth Amid Competition
by Zacks Equity Research
Charles River's (CRL) RMS arm sees lesser impact on demand than other life science sectors despite macroeconomic challenges in China.
Here's Why You Should Retain Edward Lifesciences (EW) for Now
by Zacks Equity Research
Investors are optimistic about Edward Lifesciences (EW), led by the strong performance of its SAPIEN 3 Ultra RESILIA platform and strong solvency.
Scoop up These 4 GARP Stocks to Receive Handsome Returns
by Zacks Equity Research
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. CSL, RMD, BAH and BAP are some stocks that hold promise.
Medtronic's (MDT) OmniaSecure Lead Favored in the LEADR Trial
by Zacks Equity Research
Medtronic's (MDT) OmniaSecure defibrillation lead demonstrates reliable performance in the LEADR Pivotal trial.